Stock Price Quote

TORRENT PHARMACEUTICALS LTD.

NSE : TORNTPHARMBSE : 500420ISIN CODE : INE685A01028Industry : Pharmaceuticals & DrugsHouse : Torrent
BSE2536.85-10.65 (-0.42 %)
PREV CLOSE ( ) 2547.50
OPEN PRICE ( ) 2546.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1605
TODAY'S LOW / HIGH ( )2525.00 2559.00
52 WK LOW / HIGH ( )1580.15 2745.55
NSE2539.40-7.45 (-0.29 %)
PREV CLOSE( ) 2546.85
OPEN PRICE ( ) 2540.00
BID PRICE (QTY) 2539.40 (88)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 287483
TODAY'S LOW / HIGH( ) 2523.05 2560.00
52 WK LOW / HIGH ( )1580 2744
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-07 1972
Management Info
Samir Mehta - Chairman - Managing Director
Registered Office

Address Torrent House,Off Ashram Road,,
Ahmedabad,
Gujarat-380009

Phone 079-26599000

Email investorservices@torrentpharma.com

Website www.torrentpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

06Mar USFDA issues EIR to Torrent Pharmaceut
The United States Food and Drug Administration (USFDA) has successfully..
05Feb Torrent Pharmaceuticals hits 52-week h
Torrent Pharmaceuticals is currently trading at Rs. 2679.90, up by 155.2..
03Feb Torrent Pharmaceuticals reports 52% ri
Torrent Pharmaceuticals has reported results for third quarter ended Dec..
02Feb Torrent Pharmaceuticals informs about
Torrent Pharmaceuticals has informed that the Presentation on unaudited..
12Jan Torrent Pharmaceuticals informs about
Torrent Pharmaceuticals has informed that a meeting of the Board of Dire..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit297010520
Gross Profit 4300 15770
Operating Profit 690025470
Net Sales 2123076950

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

PROMOTERS 71.25%
NON-INSTITUTION 7.45%
MUTUAL FUNDS/UTI 4.48%
FI/BANKS/INSURANCE 1.96%
GOVERNMENT 0%
FII 0%

About Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd. was incorporated in the year 1972. Its today's share price is 2536.85. Its current market capitalisation stands at Rs 85858.53 Cr. In the latest quarter, company has reported Gross Sales of Rs. 78453.1 Cr and Total Income of Rs.77770.8 Cr. The company's management includes Nikhil Khattau, Chintan Trivedi, Aman Mehta, Jinesh Shah, Manish Choksi, Maurice Chagnaud, Nayantara Bali, Ameera Shah, Samir Mehta, Sudhir Mehta.

It is listed on the BSE with a BSE Code of 500420 , NSE with an NSE Symbol of TORNTPHARM and ISIN of INE685A01028. It's Registered office is at Torrent House,Off Ashram Road,Ahmedabad-380009, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, CC Chokshi & Co, Deloite Haskins & Sells, Deloitte Haskins & Sells, Deloittee Haskins & Sells

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.